A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.
Multiple Myeloma
clinical trials
genomic aberrations
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
03
11
2020
revised:
24
11
2020
accepted:
01
12
2020
entrez:
8
12
2020
pubmed:
9
12
2020
medline:
27
7
2021
Statut:
epublish
Résumé
Multiple myeloma (MM) is a genetically heterogeneous disease, in which the process of tumorigenesis begins and progresses through the appearance and accumulation of a tangle of genomic aberrations. Several are the mechanisms of DNA damage in MM, varying from single nucleotide substitutions to complex genomic events. The timing of appearance of aberrations is well studied due to the natural history of the disease, that usually progress from pre-malignant to malignant phase. Different kinds of aberrations carry different prognostic significance and have been associated with drug resistance in some studies. Certain genetic events are well known to be associated with prognosis and are incorporated in risk evaluation in MM at diagnosis in the revised International Scoring System (R-ISS). The significance of some other aberrations needs to be further explained. Since now, few phase 3 randomized trials included analysis on patient's outcomes according to genetic risk, and further studies are needed to obtain useful data to stratify the choice of initial and subsequent treatment in MM.
Identifiants
pubmed: 33287156
pii: genes11121453
doi: 10.3390/genes11121453
pmc: PMC7761770
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Opin Genet Dev. 2020 Feb;60:41-47
pubmed: 32151946
N Engl J Med. 2015 Sep 24;373(13):1207-19
pubmed: 26308596
Methods Mol Biol. 2018;1769:231-251
pubmed: 29564828
Mol Cytogenet. 2019 Feb 11;12:6
pubmed: 30805029
Cancer Cell. 2013 May 13;23(5):567-9
pubmed: 23680143
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Leuk Res. 2019 Jan;76:58-64
pubmed: 30576858
Cell. 2015 Dec 17;163(7):1641-54
pubmed: 26687355
N Engl J Med. 2007 Jun 21;356(25):2582-90
pubmed: 17582068
Blood. 2019 May 2;133(18):1953-1963
pubmed: 30819926
Blood. 2011 Jul 21;118(3):675-8
pubmed: 21628407
J Clin Invest. 2016 Jul 1;126(7):2588-96
pubmed: 27270177
Leukemia. 2003 Feb;17(2):427-36
pubmed: 12592343
Blood Rev. 2020 May;41:100643
pubmed: 31818702
Leukemia. 2008 May;22(5):1044-52
pubmed: 18216867
Cancer Genet. 2017 Dec;218-219:1-9
pubmed: 29153091
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Lancet Haematol. 2020 Jun;7(6):e456-e468
pubmed: 32359506
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
Blood. 2011 Feb 24;117(8):2300-2
pubmed: 21350059
Blood. 2003 Oct 1;102(7):2562-7
pubmed: 12805059
Blood. 2018 Aug 9;132(6):587-597
pubmed: 29884741
Blood. 2016 Mar 3;127(9):1109-16
pubmed: 26802176
Cancer Cell. 2007 Aug;12(2):131-44
pubmed: 17692805
Arch Immunol Ther Exp (Warsz). 2016 Dec;64(Suppl 1):151-156
pubmed: 28083618
Blood. 2006 Sep 1;108(5):1733-43
pubmed: 16705090
J Clin Oncol. 2016 Aug 10;34(23):2698-704
pubmed: 27269947
Blood. 1992 Jul 1;80(1):203-8
pubmed: 1351763
Genes Chromosomes Cancer. 2011 Oct;50(10):765-74
pubmed: 21961181
J Clin Oncol. 2020 Sep 20;38(27):3107-3118
pubmed: 32687451
Ann N Y Acad Sci. 2012 Sep;1267:79-85
pubmed: 22954220
Lancet Oncol. 2019 Jan;20(1):57-73
pubmed: 30559051
Curr Opin Genet Dev. 2012 Jun;22(3):204-10
pubmed: 22365495
Blood. 2007 Nov 1;110(9):3112-21
pubmed: 17634408
Blood. 2002 Aug 15;100(4):1417-24
pubmed: 12149226
Blood. 2005 Sep 15;106(6):2156-61
pubmed: 15920009
Blood Cancer J. 2019 Sep 30;9(10):77
pubmed: 31570697
Oncotarget. 2016 Apr 19;7(16):21353-61
pubmed: 26870891
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Lancet Oncol. 2020 Oct;21(10):1317-1330
pubmed: 32866432
Cancer Res. 2007 Apr 1;67(7):2982-9
pubmed: 17409404
Blood. 2005 Jan 1;105(1):358-60
pubmed: 15339849
Blood. 2007 Apr 15;109(8):3489-95
pubmed: 17209057
Mutat Res Rev Mutat Res. 2019 Jan - Mar;779:1-35
pubmed: 31097147
Cancer Genet. 2011 Jan;204(1):3-12
pubmed: 21356186
Sci Rep. 2019 Oct 16;9(1):14884
pubmed: 31619706
Leukemia. 2014 Feb;28(2):269-77
pubmed: 23974982
Blood Cancer J. 2019 Mar 26;9(4):39
pubmed: 30914633
Blood. 1998 Aug 1;92(3):802-9
pubmed: 9680348
Nat Commun. 2019 Aug 23;10(1):3835
pubmed: 31444325
J Clin Oncol. 2009 Sep 20;27(27):4585-90
pubmed: 19687334
Blood. 2001 Nov 15;98(10):3082-6
pubmed: 11698294
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
PLoS Genet. 2009 Jan;5(1):e1000327
pubmed: 19180184
Front Oncol. 2019 Jan 09;8:665
pubmed: 30687640
Cancer Cell. 2008 Feb;13(2):167-80
pubmed: 18242516
Lancet Haematol. 2019 Sep;6(9):e448-e458
pubmed: 31327689
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Blood. 2010 Oct 14;116(15):e56-65
pubmed: 20616218
N Engl J Med. 2018 Jan 18;378(3):241-249
pubmed: 29342381
Leukemia. 1998 Jun;12(6):960-9
pubmed: 9639426
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
J Clin Oncol. 2019 Jul 1;37(19):1657-1665
pubmed: 31091136
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Haematologica. 2010 Nov;95(11):1973-6
pubmed: 20634494
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Genomics Inform. 2017 Sep;15(3):87-97
pubmed: 29020724
Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203
pubmed: 29402599
Cell. 2013 Apr 25;153(3):666-77
pubmed: 23622249
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Int J Lab Hematol. 2019 Feb;41(1):5-14
pubmed: 29971938
Nat Commun. 2014;5:2997
pubmed: 24429703
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Lancet. 2019 Jan 19;393(10168):253-264
pubmed: 30545780
Blood. 2005 Jul 1;106(1):296-303
pubmed: 15755896
Cancer Res. 2018 May 15;78(10):2449-2456
pubmed: 29703720
Cell. 2007 Dec 28;131(7):1235-47
pubmed: 18160035
Blood. 2003 Jun 1;101(11):4569-75
pubmed: 12576322
Cell. 2016 Jan 28;164(3):538-49
pubmed: 26806129
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Lancet. 2020 Jan 11;395(10218):132-141
pubmed: 31836199
Cell. 2011 Sep 16;146(6):889-903
pubmed: 21925314
Leukemia. 2018 Dec;32(12):2604-2616
pubmed: 29789651
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Genes Dev. 2013 Dec 1;27(23):2513-30
pubmed: 24298051
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Br J Haematol. 2020 May;189(4):e122-e125
pubmed: 32130732
Lancet Oncol. 2015 Dec;16(16):1617-29
pubmed: 26596670
Blood Cancer J. 2014 Mar 14;4:e191
pubmed: 24632883
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Blood. 2018 Jan 18;131(3):301-310
pubmed: 29150421
Nature. 2018 Sep;561(7724):551-555
pubmed: 30232450
Leukemia. 2018 Dec;32(12):2636-2647
pubmed: 29895955
Mol Cytogenet. 2020 Jan 28;13:3
pubmed: 32010222
Blood Cancer Discov. 2020 Nov;1(3):258-273
pubmed: 33392515
Crit Rev Oncol Hematol. 2019 Oct;142:58-67
pubmed: 31377433
Cancer Cell. 2006 Apr;9(4):313-25
pubmed: 16616336
Leukemia. 2004 Nov;18(11):1879-82
pubmed: 15385925
Cell. 2013 Mar 14;152(6):1226-36
pubmed: 23498933
Cancer Res. 1999 Sep 15;59(18):4546-50
pubmed: 10493504
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113
pubmed: 27531699
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Cancers (Basel). 2020 Feb 10;12(2):
pubmed: 32050631
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Nature. 2015 Jun 11;522(7555):179-84
pubmed: 26017310
Lancet Haematol. 2019 Dec;6(12):e616-e629
pubmed: 31624047
Blood Cancer J. 2017 Sep 15;7(9):e610
pubmed: 29016571
Leukemia. 2018 Jul;32(7):1609-1620
pubmed: 29472722